University Hospital Southampton, Southampton, UK.
Department of Plastic Surgery, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands.
J Hand Surg Eur Vol. 2022 Jan;47(1):80-88. doi: 10.1177/17531934211043307. Epub 2021 Sep 9.
In this article we take an international perspective on the use of needles, either percutaneous needle fasciotomy (PNF) or Clostridial Collagenase Histiolyticum (CCH), in treating Dupuytren's Disease (DD). Worldwide, PNF is now used more frequently. The CCH has been withdrawn from non-USA markets, which lessens its use. Different patients have different preferences, while different surgeons have different skills and opinions. The surgeon should fully consider the patient's preference and should also, in view of the scarcity of surgical resource and the potential hazard of surgery, reconsider and expand the use of a needle rather than an operation. In the future, a cheaper, yet equally safe and effective alternative to CCH, will provide a useful clinical tool for those cords, which, in the surgeon's personal Venn diagram, are too challenging for PNF, but the patient does not want to have surgery.
本文从国际视角探讨了在治疗掌腱膜挛缩症(Dupuytren's Disease,DD)中使用针的方法,包括经皮针刀松解术(Percutaneous needle fasciotomy,PNF)或胶原酶注射(Clostridial Collagenase Histiolyticum,CCH)。目前,PNF 在全球范围内的应用更为频繁,而 CCH 已从非美国市场撤出,因此其应用有所减少。不同的患者有不同的偏好,而不同的外科医生也有不同的技能和意见。外科医生应充分考虑患者的偏好,同时鉴于手术资源的稀缺性和手术的潜在风险,应重新考虑并扩大针的使用范围,而不是手术。未来,一种更便宜但同样安全有效的 CCH 替代方法,将为那些在外科医生个人的 Venn 图中,PNF 治疗过于具有挑战性但患者又不想手术的患者提供一种有用的临床工具。